Last Price$311.50.9%
Market Cap$87.2B
LTM Research & Development Expenses (R&D)
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
202.7% undervalued
Cigna Corporation Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for CI
and see if it's the right time to invest.
Cigna Corporation (CI) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Cigna CorporationCI
$0.0
N/A
N/A
N/A
Median Peer Set
$0.0
0.0%
0.0%
0.0%
Bright Health Group, Inc.BHG
$0.0
N/A
N/A
N/A
Clover Health Investments, Corp.CLOV
$0.0
N/A
N/A
N/A
Centene CorporationCNC
$0.0
N/A
N/A
N/A
CVS Health CorporationCVS
$0.0
N/A
N/A
N/A
Elevance Health Inc.ELV
$0.0
N/A
N/A
N/A
Alignment Healthcare, Inc.ALHC
$0.0
N/A
N/A
N/A
Humana Inc.HUM
$0.0
N/A
N/A
N/A
Molina Healthcare, Inc.MOH
$0.0
N/A
N/A
N/A
Oscar Health, Inc.OSCR
$0.0
N/A
N/A
N/A
UnitedHealth Group IncorporatedUNH
$0.0
N/A
N/A
N/A
CI key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 18,176.0 0.0% | 16,684.0 (8.2%) | 16,547.0 (0.8%) | 17,623.0 6.5% | 19,101.0 8.4% | 18,414.0 (3.6%) | 21,253.0 15.4% | 21,998.0 3.5% | 29,119.0 32.4% | 32,380.0 11.2% | 34,914.0 7.8% | 37,876.0 8.5% | 40,007.0 5.6% | 42,043.0 5.1% | 48,569.0 15.5% | 153,743.0 216.5% | 160,550.0 4.4% | 174,267.0 8.5% | 180,031.0 3.3% | 195,187.0 8.4% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 18,176.0 100.0% | 16,684.0 100.0% | 16,547.0 100.0% | 17,623.0 100.0% | 19,101.0 100.0% | 18,414.0 100.0% | 21,253.0 100.0% | 21,998.0 100.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Operating Expenses | (15,940.0) | 14,891.0 | 14,816.0 | 15,990.0 | 18,719.0 | 16,516.0 | 19,326.0 | 19,989.0 | 26,374.0 | 0.0 | 0.0 | 0.0 | 36,919.0 | 38,101.0 | 44,409.0 | 145,666.0 | 152,397.0 | 166,326.0 | 171,581.0 | 186,651.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 0.0 | 0.0 | 0.0 | 0.0 | 5,535.0 | 5,450.0 | 5,744.0 | 5,901.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9,750.0 | 9,830.0 | 11,141.0 | 13,315.0 | 13,660.0 | 12,791.0 | 13,110.0 | 14,370.0 |
% margin | 2,236.0 12.3% | 1,793.0 10.7% | 1,731.0 10.5% | 1,626.0 9.2% | 382.0 2.0% | 1,896.0 10.3% | 2,048.0 9.6% | 2,169.0 9.9% | 2,875.0 9.9% | 32,380.0 100.0% | 34,914.0 100.0% | 37,876.0 100.0% | 3,088.0 7.7% | 3,942.0 9.4% | 4,160.0 8.6% | 8,077.0 5.3% | 8,153.0 5.1% | 7,941.0 4.6% | 8,450.0 4.7% | 8,536.0 4.4% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 166.0 | 182.0 | 202.0 | 0.0 | 264.0 | 0.0 | 0.0 | 278.0 | 252.0 | 498.0 | 1,682.0 | 1,438.0 | 1,208.0 | 1,228.0 | 1,446.0 |
| Pre-tax Income | 2,375.0 | 1,793.0 | 1,731.0 | 1,631.0 | 378.0 | 1,898.0 | 1,870.0 | 1,968.0 | 2,477.0 | 2,176.0 | 3,304.0 | 3,327.0 | 2,979.0 | 3,606.0 | 3,581.0 | 6,570.0 | 10,868.0 | 6,790.0 | 8,397.0 | 5,513.0 |
% effective tax rate | 798.0 33.6% | 517.0 28.8% | 572.0 33.0% | 511.0 31.3% | 90.0 23.8% | 594.0 31.3% | 521.0 27.9% | 640.0 32.5% | 853.0 34.4% | 698.0 32.1% | 1,210.0 36.6% | 1,250.0 37.6% | 1,136.0 38.1% | 1,374.0 38.1% | 935.0 26.1% | 1,450.0 22.1% | 2,379.0 21.9% | 1,370.0 20.2% | 1,615.0 19.2% | 141.0 2.6% |
% margin | 1,438.0 7.9% | 1,625.0 9.7% | 1,155.0 7.0% | 1,115.0 6.3% | 292.0 1.5% | 1,302.0 7.1% | 1,345.0 6.3% | 1,327.0 6.0% | 1,623.0 5.6% | 1,476.0 4.6% | 2,102.0 6.0% | 2,094.0 5.5% | 1,867.0 4.7% | 2,237.0 5.3% | 2,637.0 5.4% | 5,104.0 3.3% | 8,458.0 5.3% | 5,370.0 3.1% | 6,704.0 3.7% | 5,164.0 2.6% |
| EPS | 3.51 | 4.25 | 3.49 | 3.94 | 1.05 | 4.75 | 4.69 | 4.65 | 5.70 | 5.28 | 7.97 | 8.17 | 7.31 | 8.92 | 10.69 | 13.58 | 23.17 | 15.89 | 21.66 | 17.57 |
| Diluted EPS | 3.48 | 4.17 | 3.43 | 3.87 | 1.05 | 4.73 | 4.65 | 4.59 | 5.61 | 5.18 | 7.83 | 8.04 | 7.19 | 8.77 | 10.54 | 13.44 | 22.96 | 15.75 | 21.41 | 17.39 |
% margin | 2,098.0 11.5% | 1,990.0 11.9% | 1,895.0 11.5% | 1,780.0 10.1% | 351.0 1.8% | 2,073.0 11.3% | 2,343.0 11.0% | 2,508.0 11.4% | 3,434.0 11.8% | 32,977.0 101.8% | 35,502.0 101.7% | 38,295.0 101.1% | 3,472.0 8.7% | 4,187.0 10.0% | 4,082.0 8.4% | 10,916.0 7.1% | 14,477.0 9.0% | 10,413.0 6.0% | 12,908.0 7.2% | 9,574.0 4.9% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Cigna Corporation's Research & Development Expenses (R&D)?
As of today, Cigna Corporation's last 12-month Research & Development Expenses (R&D) is $0.0, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Cigna Corporation's Research & Development Expenses (R&D) growth rate?
Over the last year, Cigna Corporation's Research & Development Expenses (R&D) growth was N/A. The average annual Research & Development Expenses (R&D) growth rates for Cigna Corporation have been N/A over the past three years, N/A over the past five years.